New agents in high-risk myeloma
| Agent . | ORR . | PFS . | OS . |
|---|---|---|---|
| Carfilzomib46 | HR, 25.8%; SR, 24.6% | HR, 3.5 mo; SR, 4.6 mo | HR, 9.3 mo; SR, 19 mo |
| Pomalidomide49 | del(17p), 32%; t(4;14), 22% | HR, 7.3 mo; 2.8m | HR, 12 mo; SR, 9 mo |
| Car/pom/dex51 | HR, 78%; SR, 74% | HR, 9.7 mo; SR, NR | HR, 16 mo; SR, 18 mo |
| Agent . | ORR . | PFS . | OS . |
|---|---|---|---|
| Carfilzomib46 | HR, 25.8%; SR, 24.6% | HR, 3.5 mo; SR, 4.6 mo | HR, 9.3 mo; SR, 19 mo |
| Pomalidomide49 | del(17p), 32%; t(4;14), 22% | HR, 7.3 mo; 2.8m | HR, 12 mo; SR, 9 mo |
| Car/pom/dex51 | HR, 78%; SR, 74% | HR, 9.7 mo; SR, NR | HR, 16 mo; SR, 18 mo |
Car/pom/dex, carfilzomib, pomalidomide, and dexamethasone; NR, not reported; ORR, overall response rate.